Briefing: RACER-Knee and robotic TKA: what does the evidence show?

In August 2026, RACER-Knee reported no clinically meaningful patient benefit from Mako robotic-arm-assisted total knee replacement at 12 months, despite greater surgical precision.

The discussion that followed was unusually strong. Some saw the trial as a clear answer on robotic TKA. Others questioned the alignment target, the size of the effect the trial was designed to detect, surgeon experience, cost, long-term outcomes and whether some patients might still benefit.

This brief follows those arguments back to the evidence.

It looks at what RACER-Knee really compared, what greater accuracy may or may not mean for patients, how the alignment debate changes the interpretation, what the longer-term literature can tell us, and where the current evidence still stops.

The brief covers

- what RACER-Knee found at 12 months;

- what the trial can and cannot prove statistically;

- why robotic TKA is more accurate;

- mechanical, kinematic and functional alignment;

- whether the size of an alignment error matters;

- patient and surgeon subgroups;

- long-term implant survival and revision evidence;

- operating time and infection risk;

- cost and how it changes between settings;

- what patients can reasonably be told today;

- the evidence that would move the discussion forward.

Professional online discussion was used to identify the questions, not as scientific evidence. Factual claims were checked against the RACER-Knee publications and the wider literature.

Free PDF · Fully referenced · Evidence reviewed to 28 August 2026